诺和诺德 NVO
$40.31 +$0.01 (+0.02%)
休市 · Nov 6, 8:10 pm ET · 最新盘后价 $40.34 +0.08%
开盘$39.76
昨收$40.30
当日区间$39.53 – $40.55
成交量9.24M
市值$179.98B
市盈率（TTM）10.5
股息率4.39%
NVO 相关新闻
匹配 Novo-Nordisk A/S 或代码 NVO 的头条新闻，按最新排序。
- Eli Lilly and Co (LLY.US) and Novo-Nordisk A/S (NVO.US) win GLP-1 antitrust lawsuit as U.S. court dismisses allegations by rival pharmacy 中性
- Novo-Nordisk A/S (NVO.US) Q2 earnings beat expectations and full-year guidance was raised, yet underlying concerns persist! Weak sales of oral Wegovy cast a shadow over its path back to growth. 正面
- BMO Capital Maintains Novo-Nordisk A/S(NVO.US) With Hold Rating, Maintains Target Price $47
- Defiance Daily Target 2X Long NVO ETF | NPORT-P: Others
- BMO Capital Maintains Novo-Nordisk A/S(NVO.US) With Hold Rating, Maintains Target Price $47
- TD Cowen Maintains Novo-Nordisk A/S(NVO.US) With Hold Rating, Maintains Target Price $42
- Morgan Stanley Downgrades Novo-Nordisk A/S(NVO.US) to Sell Rating, Maintains Target Price $40 负面
- Novo Resources Corp: Statement of CDIs on issue - NVO
- BMO Capital Maintains Novo-Nordisk A/S(NVO.US) With Hold Rating, Raises Target Price to $47 正面
- Analysts' Opinions Are Mixed on These Healthcare Stocks: BrightSpring Health Services, Inc. (BTSG), AbbVie (ABBV) and Novo Nordisk (NVO)
- Novo-Nordisk A/S (NVO.US) has submitted a marketing application in China for Wegovy tablets for long-term weight management.
- Defiance Daily Target 2X Long NVO ETF | 497K: Others
- Goldman Sachs Maintains Novo-Nordisk A/S(NVO.US) With Hold Rating, Raises Target Price to $47 正面
- BMO Capital Maintains Novo-Nordisk A/S(NVO.US) With Hold Rating, Maintains Target Price $45
- Goldman Sachs Maintains Novo-Nordisk A/S(NVO.US) With Hold Rating, Cuts Target Price to $40 负面
暂无评论——快来第一个聊聊 NVO。
登录后参与讨论。